Turofexorate isopropyl (BioDeep_00000175007)

   

human metabolite blood metabolite


代谢物信息卡片


Propan-2-yl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-1H,2H,3H,6H-azepino[4,5-b]indole-5-carboxylic acid

化学式: C25H24F2N2O3 (438.17548980000004)
中文名称: WAY-362450
谱图信息: 最多检出来源 Homo sapiens(blood) 20%

分子结构信息

SMILES: CC(C)OC(=O)C1=CN(CC(C)(C)C2=C1NC1=CC=CC=C21)C(=O)C1=CC(F)=C(F)C=C1
InChI: InChI=1S/C25H24F2N2O3/c1-14(2)32-24(31)17-12-29(23(30)15-9-10-18(26)19(27)11-15)13-25(3,4)21-16-7-5-6-8-20(16)28-22(17)21/h5-12,14,28H,13H2,1-4H3

描述信息

C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent

同义名列表

10 个代谢物同义名

Propan-2-yl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-1H,2H,3H,6H-azepino[4,5-b]indole-5-carboxylic acid; propan-2-yl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-1H,2H,3H,6H-azepino[4,5-b]indole-5-carboxylate; isopropyl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-2H,6H-azepino[4,5-b]indole-5-carboxylate; Turofexoric acid isopropyl; TUROFEXic acid isopropyl; FXR-450WAY-362450XL335; Turofexorate isopropyl; TUROFEXate isopropyl; FXR-450; XL335



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Weibin Wu, Qing Wu, Xinmei Liu. Chronic activation of FXR-induced liver growth with tissue-specific targeting Cyclin D1. Cell cycle (Georgetown, Tex.). 2019 08; 18(15):1784-1797. doi: 10.1080/15384101.2019.1634955. [PMID: 31223053]
  • Monica D Chow, Yi-Horng Lee, Grace L Guo. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Molecular aspects of medicine. 2017 08; 56(?):34-44. doi: 10.1016/j.mam.2017.04.004. [PMID: 28442273]
  • W B Wu, Y Y Xu, W W Cheng, Y X Wang, Y Liu, D Huang, H J Zhang. Agonist of farnesoid X receptor protects against bile acid induced damage and oxidative stress in mouse placenta--a study on maternal cholestasis model. Placenta. 2015 May; 36(5):545-51. doi: 10.1016/j.placenta.2015.02.005. [PMID: 25747729]
  • Xijun Liu, Ruyi Xue, Lingling Ji, Xingwang Zhang, Jian Wu, Jianxin Gu, Meiling Zhou, She Chen. Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction. Biochemical and biophysical research communications. 2014 Jul; 450(1):117-23. doi: 10.1016/j.bbrc.2014.05.072. [PMID: 24875360]
  • Weibin Wu, Bo Zhu, Xiaomin Peng, Meiling Zhou, Dongwei Jia, Jianxin Gu. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochemical and biophysical research communications. 2014 Jan; 443(1):68-73. doi: 10.1016/j.bbrc.2013.11.057. [PMID: 24269813]
  • Eva Hambruch, Shinobu Miyazaki-Anzai, Ulrike Hahn, Silke Matysik, Alfred Boettcher, Sanja Perović-Ottstadt, Thomas Schlüter, Olaf Kinzel, Helen Desiree Krol, Ulrich Deuschle, Michael Burnet, Moshe Levi, Gerd Schmitz, Makoto Miyazaki, Claus Kremoser. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice. The Journal of pharmacology and experimental therapeutics. 2012 Dec; 343(3):556-67. doi: 10.1124/jpet.112.196519. [PMID: 22918042]
  • Hans G F Richter, G M Benson, K H Bleicher, D Blum, E Chaput, N Clemann, S Feng, C Gardes, U Grether, P Hartman, B Kuhn, R E Martin, J-M Plancher, M G Rudolph, F Schuler, S Taylor. Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties. Bioorganic & medicinal chemistry letters. 2011 Feb; 21(4):1134-40. doi: 10.1016/j.bmcl.2010.12.123. [PMID: 21269824]
  • Songwen Zhang, Juan Wang, Qiangyuan Liu, Douglas C Harnish. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. Journal of hepatology. 2009 Aug; 51(2):380-8. doi: 10.1016/j.jhep.2009.03.025. [PMID: 19501927]
  • Helen B Hartman, Stephen J Gardell, Chris J Petucci, Shuguang Wang, Julie A Krueger, Mark J Evans. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. Journal of lipid research. 2009 Jun; 50(6):1090-100. doi: 10.1194/jlr.m800619-jlr200. [PMID: 19174369]
  • Mark J Evans, Paige E Mahaney, Lisa Borges-Marcucci, KehDih Lai, Shuguang Wang, Julie A Krueger, Stephen J Gardell, Christine Huard, Robert Martinez, George P Vlasuk, Douglas C Harnish. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. American journal of physiology. Gastrointestinal and liver physiology. 2009 Mar; 296(3):G543-52. doi: 10.1152/ajpgi.90585.2008. [PMID: 19136377]